URGN
UroGen Pharma Ltd.
Next earnings Aug 5, 2026 · consensus $-0.31 EPS, $62.8M rev
Last earnings +10.2% on 2026-05-06
$34.54
▲ +0.47%$34.54▲ +141.54%
over 1Y
L $12.96EODHDH $35.42
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+0.5%
1W-1.3%
1M+17.8%
3M+101.2%
YTD+52.1%
1Y+141.5%
Avoid
Conviction
Horizon
Medium (3–12mo)
Street · 14 analysts
Buy
Revenue grew 21.4% YoY; but unprofitable (net margin -139.8%).
Revenue (FY2025) $110M · FY2025
UroGen Pharma Ltd. shows $110M in FY2025 revenue (+21.4% YoY), a -139.8% net margin.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $48.0M | $64.4M | $82.7M | $90.4M | $110M |
| Gross profit | $42.9M | $56.7M | $73.4M | $81.5M | $97.3M |
| Operating income | -$92.3M | -$79.0M | -$65.5M | -$96.8M | -$125M |
| Net income | -$111M | -$110M | -$102M | -$127M | -$153M |
| Diluted EPS | -$4.96 | — | — | — | — |
| Net margin | -230.7% | -170.6% | -123.6% | -140.4% | -139.8% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$1.69B
EV / EBITDA—
EV / Sales15.4
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-9.1%
FCF yield-9.7%
Quality & risk
ROIC (est.)—
Free cash flow-$163M
Total debt$122M
Net cash-$11.5M
Altman Z-Score-4.08 distress
Piotroski F-Score1/9
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY+5.6%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsSome governance/structural items recently, but no outright red flags.
Recent filings
all on EDGAR ↗4Period ending 2026-06-222026-06-24open ↗4Period ending 2026-06-222026-06-24open ↗4Period ending 2026-06-222026-06-24open ↗4Period ending 2026-06-222026-06-24open ↗4Period ending 2026-06-222026-06-24open ↗4Period ending 2026-06-222026-06-24open ↗4Period ending 2026-06-222026-06-24open ↗8-KPeriod ending 2026-06-222026-06-23open ↗144Filing2026-06-22open ↗4Period ending 2026-06-082026-06-09open ↗144Filing2026-06-09open ↗8-KPeriod ending 2026-06-022026-06-02open ↗
Frequently asked
- Is UroGen Pharma Ltd. (URGN) a buy?
- URGN currently carries a Avoid rating with 2/5 conviction, derived from its latest SEC filings. Revenue grew 21.4% YoY; but unprofitable (net margin -139.8%).
- What is UroGen Pharma Ltd.'s quality score?
- URGN scores 27.176470588235293/100 (grade F) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001668243, latest 10-Q filed 2026-05-06) · EODHD · as of 6/26/2026, 6:52:58 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.